Featuring perspectives from Dr Reva Basho, Ms Kelly Fischer, Ms Melissa Rikal and Dr Seth Wander, moderated by Dr Wander, including the following topics:
- Introduction (00:00)
- Identification of Appropriate Candidates for Agents Targeting the PI3K/AKT/mTOR Pathway (3:45)
- Role of Inavolisib in HR-Positive Metastatic Breast Cancer (mBC) (13:00)
- Strategies to Prevent and Manage Hyperglycemia (27:02)
- Clinical Utility of Capivasertib for HR-Positive mBC (38:09)
- Mitigation and Management of Gastrointestinal Adverse Events (51:05)
- Management of Dermatologic Adverse Events (59:58)
- Potential Role of Gedatolisib in the Management of HR-Positive mBC (1:08:42)
- Monitoring and Management of Cytopenias (1:21:23)
CME information and select publications
